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Abstract
Background: Apical Membrane Antigen 1 (AMA1), a polymorphic merozoite surface protein, is a leading blood-stage
malaria vaccine candidate. This is the first reported use in humans of an investigational vaccine, AMA1-C1/Alhydrogel, with
the novel adjuvant CPG 7909.
Methods: A phase 1 trial was conducted at the University of Rochester with 75 malaria-naive volunteers to assess the safety
and immunogenicity of the AMA1-C1/Alhydrogel+CPG 7909 malaria vaccine. Participants were sequentially enrolled and
randomized within dose escalating cohorts to receive three vaccinations on days 0, 28 and 56 of either 20 mg of AMA1-C1/
AlhydrogelH+564 mg CPG 7909 (n=15), 80 mg of AMA1-C1/AlhydrogelH (n=30), or 80 mg of AMA1-C1/Alhydrogel+564 mg
CPG 7909 (n=30).
Results: Local and systemic adverse events were significantly more likely to be of higher severity with the addition of CPG
7909. Anti-AMA1 immunoglobulin G (IgG) were detected by enzyme-linked immunosorbent assay (ELISA), and the immune
sera of volunteers that received 20 mgo r8 0mg of AMA1-C1/Alhydrogel+CPG 7909 had up to 14 fold significant increases in
anti-AMA1 antibody concentration compared to 80 mg of AMA1-C1/Alhydrogel alone. The addition of CPG 7909 to the
AMA1-C1/Alhydrogel vaccine in humans also elicited AMA1 specific immune IgG that significantly and dramatically
increased the in vitro growth inhibition of homologous parasites to levels as high as 96% inhibition.
Conclusion/Significance: The safety profile of the AMA1-C1/Alhydrogel+CPG 7909 malaria vaccine is acceptable, given the
significant increase in immunogenicity observed. Further clinical development is ongoing.
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Introduction
As reported by the World Health Organization (WHO) in 2005,
the worldwide incidence of malaria is approximately 350–
500 million clinical episodes annually, with more than 1 million
deaths per year attributed to malaria alone and many additional
deaths caused through synergy with other diseases [1]. Most of this
mortality occurs among children under 5 years of age in sub-
Saharan Africa. Of the 4 species of malaria that infect humans, P.
falciparum is responsible for the majority of these deaths. Mounting
drug resistance of the malaria parasite, as well as widespread
resistance of mosquitoes to insecticides, make these control
strategies increasingly problematic. A vaccine that would reduce
both mortality and morbidity secondary to P. falciparum infection
would be a valuable resource in the fight against this disease.
The asexual blood-stage merozoite surface antigen Apical
Membrane Antigen 1 (AMA1) has been shown in several
preclinical studies to be a promising malaria vaccine candidate
[2–6]. Alignments of published P. falciparum AMA1 gene sequences
from different isolates reveal that the AMA1 gene occurs as
distinct allelic variants that differ by a number of point mutations,
resulting in at least 64 known polymorphisms in the amino acid
PLoS ONE | www.plosone.org 1 August 2008 | Volume 3 | Issue 8 | e2940sequence [7–13]. Immunization with only one form of AMA1 may
not protect against parasites expressing different AMA1 alleles.
The combination of two or more divergent AMA1 alleles within a
single vaccine formulation may provide broader protection against
parasites with varying AMA1 sequences in the field, if some degree
of cross-strain protection is induced [14,15]. For this reason, the
AMA1-C1 vaccine contains equal mixtures of the recombinant
AMA1 proteins derived from the FVO and 3D7 strains of P.
falciparum.
Four previous studies in the US and Mali have evaluated
AMA1-C1 formulated on AlhydrogelH without CPG 7909 [16–
19]. Some volunteers in the US Phase 1 clinical trial achieved
AMA1 antibody levels that partially blocked P. falciparum invasion
of erythrocytes; however, the majority of volunteers displayed low
antibody levels with little or no in vitro inhibition of parasite
invasion [16]. Antibody responses in semi-immune Malian adults
were superior to those seen in the US, and responses were seen
after the first dose [17]. We believed that higher antibody
responses would be more likely to lead to protection. AMA1 has
also been tested in humans in combination with other adjuvants
such as AS02A, AS01B and Montanide ISA 720 [20,21].
The novel adjuvant CPG 7909 (VaxImmune
TM), a CpG
oligodeoxynucleotide (ODN), has been administered to humans
in combination with hepatitis B vaccine, inactivated influenza
vaccine, and anthrax vaccine [22–25]. Results from these trials
indicated that, although adverse events were more frequent in
some studies, [22–24] the addition of CPG 7909 was acceptable,
and in the case of the alum-adjuvanted hepatitis B and anthrax
vaccines, induced significantly higher and earlier antibody
responses than the vaccine alone. Preclinical and formulation
studies with CPG 7909 added to AMA1-C1/AlhydrogelH also
showed significant enhancement of antibody responses in animal
models. [26–28] Therefore, we evaluated CpG ODN adjuvant in
combination with AMA-C1/Alhydrogel in a phase 1 clinical trial.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study design
The study was conducted as a single-blind, randomized, dose
escalating Phase 1 clinical trial in healthy volunteers, designed to
evaluate the safety, reactogenicity, and immunogenicity of the
AMA1-C1 vaccine formulated on AlhydrogelH and mixed with
CPG 7909. The study was performed in three sequential cohorts,
and escalation between cohorts did not occur until the previous
cohort had received two vaccinations and the safety data from this
group had been reviewed by a Safety Monitoring Committee.
The study was conducted under a protocol reviewed and approved
by the Institutional Review Board (IRB) of the National Institute of
Allergy and Infectious Disease (NIAID), and by the University of
Rochester Research Subjects Review Board. The study was
submitted to the U.S. Food and Drug Administration for review as
part of Investigational New Drug application BB-IND#12029. The
study was monitored for regulatory compliance and data quality by
the Division of Microbiology and Infectious Diseases (DMID) of
NIAID. Written informed consent was obtained from all volunteers
prior to screening for eligibility for participation
Participants
Participants were healthy volunteers between 18 and 45 years
old recruited in the Rochester, New York area. Exclusion criteria
included prior malaria infection, recent or planned travel to a
malaria endemic country, and recent use of malaria prophylaxis.
Because of the theoretical risk of inducing autoimmunity with
CpG ODNs, potential subjects were screened for positive anti-
double stranded DNA (ds-DNA), rheumatoid factor (RF), anti-
nuclear antibody (ANA) and proteinuria. Volunteers also had
normal results for screening laboratories (complete blood count,
aspartate aminotransferase (AST), creatinine), no serologic
evidence of hepatitis B or C infection, or antibody to human
immunodeficiency virus. Urine pregnancy testing was performed
at screening as well as prior to each vaccination for females.
Interventions
AMA-1 antigens were expressed in the yeast Pichia pastoris, and
20 mg and 80 mg doses of AMA1-C1/AlhydrogelH were manu-
factured under cGMP conditions as previously described [14,16].
cGMP CPG 7909 was supplied by Coley Pharmaceutical Group
(Wellesley, MA) under a clinical trials agreement. CPG 7909 is a
short synthetic ODN with a sequence of 59-TCG TCG TTT TGT
CGT TTT GTC GTT-39 with all nucleotides linked with
phosphorothioate bonds. CPG 7909 was supplied in sterile vials
containing 1 mL at 10 mg/mL in hypertonic phosphate buffer at
a pH 7.4. AMA1-C1/Alhydrogel+CPG 7909 was prepared as a
point of injection formulation. Characterization and quality
control were performed as previously described [27,28]. Shortly
before vaccination, 0.08 mL of CPG 7909 was drawn into a
0.30 mL (insulin) syringe and added to a single dose (0.7 mL) vial
of AMA1-C1/Alhydrogel and gently mixed. The vaccine was
administered no more than 6 hours after mixing and was kept at
4uC if not immediately administered. When ready to administer,
0.55 mL was withdrawn into a syringe, and the vaccine injected.
Vaccine was given by intramuscular injection into the deltoid
muscle on Days 0, 28, and 56, with successive vaccinations given
in alternating arms. A 0.55 mL dose of AMA1-C1/Alhydro-
gel+CPG 7909 corresponds to either 20 mgo r8 0mg of AMA1-C1
and 564 mg of CPG 7909.
Participants were sequentially enrolled and randomized within
three dose escalating cohorts. In the first cohort, subjects were
randomized to receive either 80 mg of AMA1-C1/AlhydrogelH
(80 mg AMA1, n=5), or 20 mg of AMA1-C1/Alhydro-
gelH+564 mg CPG 7909 (20 mg AMA1+CPG, n=15). In the
second cohort, subjects received either 80 mg AMA1/AlhydrogelH
(n=5) or 80 mg of AMA1-C1/Alhydrogel+564 mg CPG 7909
(80 mg AMA1+CPG, n=15). In the third cohort, subjects received
either 80 mg AMA1/AlhydrogelH (n=20) or 80 mg AMA1/
AlhydrogelH+564 mg CPG 7909 (n=15). Randomization was
performed using the enrolment module of the Internet Data Entry
System (IDES), with the code list stored in a secured location at the
study site. Participants remained blinded to their treatment
assignment for the duration of the study.
Outcomes
(i) Safety. Volunteers were observed for 30 minutes after
each vaccination to evaluate for immediate adverse events, and
were given diary cards to record events occurring during the first
week after vaccination. Volunteers were seen in the study clinic at
3, 7, and 14 days after each vaccination, and at 28, 84, and 180
days after the third vaccine dose. Solicited adverse events included
injection site pain, erythema, and induration, fever, headache,
nausea, myalgia, arthralgia, and rash. Pain and solicited adverse
events other than fever and urticaria were graded as follows:
0=absent/none, 1=easily tolerated, 2=interferes with daily
activity, 3=prevents daily activity. Unless otherwise specified,
non-solicited adverse events were graded as 0=none, 1=no effect
AMA1/CPG 7909 Malaria Vaccine
PLoS ONE | www.plosone.org 2 August 2008 | Volume 3 | Issue 8 | e2940on activities of daily living, 2=partial limitation in activities of
daily living, or treatment given, 3=activities of daily living limited
to ,50% of baseline, or medical evaluation required.
Hematological (Hb, WBC, and platelets) and biochemical (AST
and creatinine) laboratory parameters were measured at screening
and on days of immunization, and at 3 and 14 days after each
vaccination; hematological parameters were also checked on Days
7. Anti-dsDNA, ANA, and RF were checked at screening, each
day of vaccination, and at 7 days after each dose and 28 days after
the third dose, and at the end of the study. All adverse events were
graded for severity and relationship to study product. Adverse
events which were unlikely, possibly, probably or definitely related
to vaccination were considered to be associated with vaccination;
adverse events definitely unrelated to vaccination were not
associated. Serious adverse events (SAEs) were defined as any
adverse event resulting in death, life threatening, requiring
hospitalization, resulting in disability or incapacity or congenital
anomaly or birth defect, or any other event which required
intervention to prevent such outcomes.
(ii)ImmunologicalAssays. AntibodyresponsestotheAMA1
antigens were measured by enzyme linked immunosorbent assay
(ELISA) on Days 0, 14, 28, 42, 56, 70, 84, 140 and 236. The
standardized ELISA technique was performed as described
previously [16,17,29]. A new human anti-AMA1 standard serum
was made using a pool of plasma from 3 individuals receiving
AMA1-C1/Alhydrogel+CPG 7909 vaccine in this study. The
standard pool was assigned 460.9 Malaria Vaccine Development
Branch (MVDB) ELISA units on AMA1-FVO and 578.0 units on
AMA1-3D7. The AMA1 specific antibody concentration in the
standard pool gave 0.0584 (SE60.0012) mg/mL of AMA1-FVO-
specific IgG for 1 ELISA unit, and 0.0473 (SE60.0016) mg/mL of
AMA1-3D7-specific IgG for 1 ELISA unit. The methods used to
determine the concentrationwill be reported elsewhere(Miura et al,
manuscript in preparation). Using these factors, all MVDB ELISA
units were converted to mg/mL. Minimal detection level of this
ELISA was 1.66 mg/mL and all values less than that were assigned
as 0.83 mg/mL for statistical analysis.
In vitro parasite growth inhibition of homologous FVO and
3D7 P.falciparium strains was performed on sera from all volunteers
on Days 0 and 70 using a standardized growth inhibition assay
(GIA) as previously reported [16,17]. GIA was performed using
total IgG purified from individual sera and concentrated to
40 mg/mL. The final concentration of total IgG in the GIA wells
was 10 mg/mL. The anti-AMA1 antibody concentrations (mg/
mL) shown are the concentration of specific antibody in test wells.
Heterologous in vitro parasite growth inhibition of L32 [13] and
M24 [14] strains of parasites were performed. Due to the
limitation of volume of purified IgGs, only ten total IgG samples
with high growth-inhibitory activity to homologous parasites
($68% inhibition to 3D7 parasites) were tested.
Samples were excluded from the ELISA and GIA statistical
analysis for the time points after the first missed vaccination of
volunteers who withdrew or were withdrawn from the study or if
samples were unavailable.
Statistical analysis
(i) Adverse Events. The frequency of adverse events
stratified by dose cohort was summarized. Logistic regressions
were used to investigate the effect of dose group on either local,
systemic or laboratory adverse events. In each logistic regression,
the response used for each subject was the most severe response
observed, and all subjects were included regardless of withdrawal
status. For the local or systemic reactions separate regressions were
done for the odds of experiencing any reaction (mild, moderate, or
severe vs. none) or higher severity reactions (moderate or severe vs.
none or mild). When a dose group effect was found to be
significant, pairwise tests using the same model were used to
further investigate specific comparisons. No corrections were made
for multiple comparisons. Statistical analysis for adverse events was
performed by an independent data management group (EMMES
Corporation) using SAS Version 9.1 (SAS Institute Inc., Cary,
NC), and results were reviewed by the study statistician (MPF).
(ii) Antibody responses. To further delineate differences in
antibody responses or in vitro parasite growth inhibitions between
the 80 mg AMA1, 20 mg AMA1+CPG, and 80 mg AMA1+CPG
groups, a Kruskal-Wallis test was performed for ELISA results
with sera obtained on Days 42, and when found to be significant at
the 0.05 level, was followed by a pairwise comparison using the
Mann-Whitney U test at the 0.05 level with the associated
Hodges-Lehmann confidence intervals. This procedure is known
to bound the family-wise type I error at 0.05 [30]. We repeated the
procedure for Day 70 ELISA and Day 70 GIA. To test for an
accelerated CPG effect we compared the 80 mg AMA1 group to
the 80 mg AMA1+CPG group by Mann-Whitney U test. For
comparison of Day 42 and Day 70 AMA-FVO and AMA1-3D7
titers within the groups, a Wilcoxon signed rank test was used with
Hodges-Lehmann confidence intervals. To determine significant
differences between growth inhibition on the 4 parasite strains
(3D7, FVO, L32, and M24), we used an all-subset procedure with
Friedman’s test, with the family-wise p-value defined as the lowest
family-wise significance level that declares all pairs significantly
different [30]. StatXact 8 Procs (Cytel Inc., Cambridge, MA,
USA) was used for these analyses and P values of ,0.05 were
considered significant for both antibody and adverse event
analyses.
To model the relationship between anti-AMA1 antibodies (X)
and growth inhibition (Y), we used a Hill function:
Y~
100 X
b
 a
1z X
b
 a
where a is the Hill coefficient, and b is the Ab50 (amount of
antibody needed to give 50% growth inhibition). We fit the model
by nonlinear least squares. We used an F test to see if calculating a
separate Hill function for each vaccine group significantly
improved the fit. Calculations were done in R 2.6.1 [31].
(iii) Sample size. The group size of 15 subjects for the 20 mg
AMA1+CPG group, included for safety, gave a probability of about
0.8 for detecting one or more serious or severe AE that occur with a
frequency of 0.1 per volunteer. The larger groups (80 mg AMA1
with and without CPG) were sized for a comparison of
immunogenicity. Based on an analysis of the human antibody
responses to a number of malaria antigens that had been previously
tested in clinical trials, the observed coefficient of variation in the
range of antibody concentrations was approximately 1.2–1.4.
Assuming the larger coefficient of variation and assuming that one
group had mean antibody concentrations that were at least 2.2
timesthemean antibody concentrations oftheothergroup,then the
two-sided Mann-Whitney test assuming a significance of 0.05
performed on a sample size of 30 per group would have a power of
greater than 0.80.
Results
Participant flow
The study was conducted at the University of Rochester School
of Medicine from April 2005 to March 2007. 184 volunteers were
screened to sequentially enroll 75 participants in three cohorts as
AMA1/CPG 7909 Malaria Vaccine
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Fifteen participants did not complete the 3 dose vaccination series:
two volunteers withdrew; 9 were withdrawn due to clinical or
laboratory AEs associated with vaccination (unlikely, possibly,
probably and definitely related), and 4 were withdrawn due to AEs
not associated (definitely not related) with vaccination, including
one volunteer who became pregnant as described below. Subjects
who were withdrawn continued to be followed for adverse events,
and in total 72/75 volunteers completed follow up to day 236.
Safety and reactogenicity
Local reactogenicity and solicited systemic events are summa-
rized in Table 1. Local reactions were mild or moderate, with the
exception of one volunteer in the 80 mg AMA1 group who
reported 150 mm induration at the injection site in a symptom
diary starting on the day of the third vaccination and resolving 3
days later, and one volunteer in the 80 mg AMA1+CPG group
who reported severe erythema 3 days after the second vaccination
which lasted one day.
Local reactions were significantly more likely in the 80 mg
AMA1+CPG group versus the 80 mg AMA1 group (OR 14.50,
95% CI 1.72–122.40, p=0.0140), and reactions were more likely to
be of a higher severity (moderate or severe versus mild or none) (OR
15.54, 95% CI 3.81–63.36, p=0.0001). Combining the CPG
groups also showed a higher likelihood of a local reaction (OR
20.00, 95% CI 1.75, 480.26, p=0.019), and a higher likelihood of a
more severe local reaction (OR 50.88, 95% CI 3.26–794.32,
p=0.0051) versus the group which did not receive CPG. When
testing for an overall dose group effect on solicited systemic events,
there was no significant difference when measuring any events
(p=0.546), but there was a significant difference for higher severity
events (p=0.024). Volunteers in the 80 mg AMA1+CPG group
were significantly more likely to experience a higher severity event
compared to the 80 mg AMA1 group (OR 4.57, 95% CI 1.45–
14.39, p=0.0094). Combining the CPG groups also showed a
higher probability of a more severe systemic event in comparison to
the non-CPG group (OR 9.14, 95% CI 1.01, 83.04, p=0.0493).
Three volunteers were withdrawn due to rash related to
vaccination. One volunteer receiving 20 mg AMA1+CPG devel-
oped a grade 1 papular non-pruritic rash on his chest, back, and
upper arms 7 days after receiving his second vaccination. A
dermatologic consultation was obtained and folliculitis/acne
possibly related to vaccination was diagnosed. The rash lasted
45 days and he was not revaccinated. One volunteer receiving
80 mg AMA1+CPG developed a grade 1 erythematous, papular,
non-pruritic rash on her chest and back 5 days after first
vaccination. The rash had substantially subsided by day 28 and
the volunteer received a second vaccination on Day 28. On Day
31 there were increased macules in the same distribution and a
decision was made not to administer the third vaccination. The
rash was completely resolved by Day 58. The third volunteer
developed a grade 2 rash 17 days after receiving his first
Figure 1. Participant Flow. Reasons for exclusion: Abnormal labs (48: 28 positive ANA, 9 positive RF, 1 positive anti-dsDNA, 10 other) Medical
history (21) No show (19) Other (21).
doi:10.1371/journal.pone.0002940.g001
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PLoS ONE | www.plosone.org 6 August 2008 | Volume 3 | Issue 8 | e2940vaccination with 80 mg AMA1; this was a fine papular rash on the
trunk, arms, and legs associated with itchy eyes and rhinitis. Tests
for mononucleosis and streptococcal infection done by the primary
physician were negative and the rash resolved after 4 days.
Another volunteer was withdrawn due to Grade 3 epigastric pain
after second vaccination with 80 mg AMA1+CPG. Other Grade 3
AEs judged to be possibly related to vaccination included
vomiting, loss of appetite, body aches, and fatigue. All Grade 3
systemic AEs resolved within 3 days.
Three volunteers were withdrawn due to a positive ANA. One
volunteer who received 20 mg AMA1+CPG was positive (1:80) on
Day 0 and continued to have low level fluctuations until the end of
the study; RF and anti-dsDNA remained normal and this was
considered not associated with vaccination. ANA elevations in the
other two volunteers were considered associated with vaccination.
One volunteer received 80 mg AMA1 without CPG; this volunteer
had a mild elevation (1:80) on the day of second vaccination which
returned to normal 6 weeks later; RF and anti-dsDNA remained
normal throughout. One volunteer who also received 80 mg
AMA1 without CPG had a normal ANA at baseline, with a mild
elevation (1:80) 7 days after vaccination and 1:1280 at second
vaccination; this volunteer also had intermittently positive RF.
After consultation with the safety monitoring committee, the
protocol was amended to allow continued participation if ANA
was positive at vaccination, as long as anti-dsDNA and proteinuria
were both negative. Subsequently, four volunteers had ANAs of
1:80 either at day of first vaccination, day of second vaccination, or
early in their participation; all received three doses of vaccine as
per protocol and all returned to normal, with some low level
fluctuations. Three of these four volunteers received vaccine with
CPG. One volunteer was withdrawn due to positive anti-dsDNA
(82 IU, normal 0–70) 7 days after first vaccination with 20 mg
AMA1+CPG; ANA and RF remained negative throughout and
anti-dsDNA was negative when rechecked 21 days later. No
volunteers had clinical evidence of autoimmune disease. The other
two withdrawals associated with vaccination were due to low
hemoglobin in a volunteer who received two doses of 20 mg
AMA1+CPG, and one volunteer who received one dose of 80 mg
AMA1 who experienced a worsening of pre-existing chest pain
related to anxiety.
Laboratory adverse events are summarized in Table 2. There
are no significant differences between study groups for any
parameter. Transient decreases in white blood cells and platelets
are an expected observation with administration of CPG 7909
[32]. In this study there were no adverse events as a result of
decreases in platelets. Most decreases in WBCs were mild (Grade
1), with 1 volunteer in the 20 mg AMA1+CPG group and one in
the 80 mg AMA1 group experiencing a Grade 2 decrease. Several
volunteers distributed among the dose groups had decreases in
hemoglobin, thought by the PI and SMC to be related to the
volume of blood drawn during the study (a total of 770 mL, with
655 mL drawn during the first 90 days). Several volunteers in both
the CPG and non CPG groups had mild elevations of RF (10 to
40 IU); all returned to normal (,10 IU) within 14 days except for
one volunteer who received 80 mg AMA1+CPG and had a
persistent titer of 10 IU at the end of the study with no other
laboratory or clinical abnormalities.
Serious adverse events
Five SAEs were reported in this study. All were assessed by the
investigators as either unrelated (situational depression, rib
fracture, testicular cancer, recurrence of bipolar disorder) or
unlikely related (pregnancy with miscarriage) to study treatment or
participation. Of note, one volunteer was found to be pregnant at
the visit scheduled for her third vaccination, which she did not
receive. Viability of the pregnancy was not confirmed by
ultrasound or serial HCG and she subsequently had a spontaneous
miscarriage. This event was judged by the investigators to be
unlikely related to vaccination due to the volunteer’s history of
polycystic ovarian disease, which is associated with early
pregnancy loss [33].
Immune responses to AMA1
(i) Anti-AMA1 IgG antibodies. Antibody levels against the
constituent AMA1 alleles in the vaccines were measured by ELISA
at different time points following vaccination. Antibody responses to
AMA1-3D7 and AMA1-FVO were measured separately to study
the contribution of each allele to the overall antibody response.
ResultsforFVOweresimilartothosefor3D7andarenotpresented
in the text (see Figure 2B and Figure 3B for FVO results).
The protocol anticipated maximum antibody responses on Day
70, 14 days after third vaccination; however, the increase in
antibody responses from Day 42 to Day 70 was significant only for
the 80 mg AMA1 group, as shown by the estimates of fold change
with 95% confidence intervals and p-values. The difference
between the Day 42 and Day 70 results for the anti-AMA1-3D7
responses for each group are: 80 mg AMA1 (2.37 fold change,
95% CI 1.53–3.67, p=0.0001), 20 mg AMA1+CPG (1.17 fold
change, 95% CI 0.81–2.06, p=0.432), and 80 mg AMA1+CPG
(1.12 fold change, 95% CI 0.99–1.26, p=0.075).
Kruskal-Wallis tests showed significant differences between
80 mg AMA1, 20 mg AMA1+CPG and 80 mg AMA1+CPG
groups for Day 42 and 70 anti-AMA1-3D7 responses derived
from individual sera (all p,0.0001, Figure 2). Pair-wise compar-
isons of the anti-AMA1-3D7 responses between the groups
revealed that on Day 42 the 20 mg AMA1+CPG or 80 mg
AMA1+CPG antibody responses were respectively 11.57 (95% CI
5.72–25.98) and 14.24 (95% CI 9.22–26.60) fold higher than those
observed with the 80 mg AMA1 group and that the differences
were significant (for both cases P,0.0001). However, the 80 mg
AMA1+CPG group was not significantly higher (fold change of
1.15, 95% CI 0.78–1.81, p=.4194) than the 20 mg AMA1+CPG
group on Day 42.
Comparisons of the antibody responses between the groups
revealed that on Day 70 the 20 mg AMA1+CPG or 80 mg
Table 2. Percentage of Subjects with Abnormal Laboratory
Results.
Parameter Study Group
20 mg+CPG 7909 80 mg8 0 mg+CPG 7909
(N=15) (N=30) (N=30)
%% %
Elevated AST 13.3 10.0 0
Elevated Creatinine 0 3.3 3.3
Decreased hemoglobin 26.7 6.7 10.0
Decreased platelets 0 0 0
Decreased WBC 6.7 30.0 30.0
ANA 6.7 13.3 16.7
Anti-ds DNA 6.7 0 0
Rheumatoid Factor 6.7 3.3 20.0
Proteinuria 6.7 6.7 16.7
doi:10.1371/journal.pone.0002940.t002
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and 5.50 (95% CI 3.80–7.91) fold higher than those observed with
the 80 mg AMA1 group for AMA1-3D7 (for both cases
P,0.0001). The 80 mg AMA1+CPG group was not significantly
higher (fold change of 1.01 95% 0.68–1.39, p=.9220) than the
20 mg AMA1+CPG group on Day 70.
The addition of CPG 7909 to 80 mg AMA1 accelerated the
anti-AMA1 antibody production. The 80 mg AMA1+CPG group
was significantly higher than the 80 mg AMA1 group at both Day
14 and Day 28 (p,0.0001 for both).
Longevity of antibody responses was investigated by plotting the
mean Day 0 to Day 236 anti-AMA1-3D7 and anti-AMA1-FVO
responses derived from individual sera for 80 mg AMA1, 20 mg
AMA1+CPG and 80 mg AMA1+CPG groups (Figure 3). Antibody
levels on day 236, the last day of the study, declined from their
peak on Day 70. At Day 236, the 20 mg AMA1+CPG and 80 mg
AMA1+CPG groups were still significantly higher than the 80 mg
AMA1 group for 3D7, with fold changes of 2.90 (95% CI 1.73–
5.10, p,0.0001) and 4.65 (95% CI 3.14–7.20, p,0.0001),
respectively. At Day 236 there is a small but significant increase
of the 80 mg AMA1+CPG group over the 20 mg AMA1+CPG
group (fold change of 1.61, 95% CI 1.06–2.13, p=0.021).
All of the above statistical analyses give similar results for both
anti-AMA1 3D7 and FVO responses.
(ii) In vitro growth inhibition assay. To determine
whether antibodies elicited by immunization had functional
activity against homologous P. falciparum parasites, we tested the
abilities of Day 70 sera to inhibit in vitro growth of the P. falciparum
3D7 and FVO parasite strains. To minimize the possibility of non-
specific in vitro inhibition of parasite growth and to ensure that the
inhibitory activity was attributable to the antibodies alone, we used
IgG purified from each serum sample (Figure 4). Substantial
inhibition of both P. falciparum 3D7 and FVO parasite growth was
achieved for the 20 or 80 mg AMA1+CPG groups with inhibitions
ranging from 16 to 96% for 3D7 (arithmetic means 65 and 66%,
respectively) and 5–96% for FVO (arithmetic means 40 and 44%).
For the 80 mg AMA1 group, the in vitro growth inhibitions ranged
from 24 to 72% for 3D7 (arithmetic mean 16%) and 28 to 58%
for FVO (arithmetic mean 6%); prevaccination IgG showed ,1%
mean inhibition. There was a significant vaccine group effect
overall for both 3D7 and FVO (p,0.0001 for both). Both CPG
groups had significantly higher inhibition than the 80 mg AMA1
group; the 20 mg AMA1+CPG group had a higher inhibition than
the 80 mg AMA1 group by 54.5 percentage points for 3D7 (95%
Figure 2. Anti-AMA1 antibody responses: Day 42 and 70 AMA1 antibody responses in recipients of the 20 or 80 mg AMA1-C1/
Alhydrogel6CPG 7909 vaccines. Antibody responses against AMA1-3D7 (A) and AMA1-FVO (B) measured by ELISA in sera collected on Day 42
(14 days postvaccination 2) and Day 70 (14 days postvaccination 3). ELISA results are shown as the geometric mean of AMA1-specific antibody (mg/
mL) with standard error. The bars represents 80 mg AMA1 (white bar, n=25), 20 mg AMA1+CPG (grey bar, n=12), and 80 mg AMA1+CPG (black bar,
n=29).
doi:10.1371/journal.pone.0002940.g002
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p,0.0001), and the 80 mg AMA1+CPG group had a higher
inhibition than the 80 mg AMA1 group by 53 percentage points
for 3D7 (95% CI 41–65, p,0.0001) and 36 for FVO (95% CI 29–
47, p,0.0001). There were no significant differences between the
20 mg and 80 mg AMA1+CPG groups, although the 80 mg
AMA1+CPG group had non-significantly higher inhibition: for
3D7 it was higher by 0.5 percentage points (95% CI 217–16,
p=0.950) for FVO it was higher by 7 percentage points (95% CI
26–23, p=0.353). The Day 42 data give similar values (results not
shown). IgG samples with the highest growth-inhibitory activity
were tested for specificity of inhibition by reversal of the GIA using
specific antigen. Inclusion of AMA1 antigen in the GIA completely
reversed the inhibition seen (data not shown), establishing the
specificity of the biological activity.
Although there was a significant difference of growth-inhibitory
activity between groups with and without CPG, it was not clear
whether the difference in activity was caused only by differences in
amount of antibody between the groups or whether antibody
elicited by the vaccines containing CPG had greater biologic
activity. Therefore the individual Day 70 data against 3D7
parasite was plotted as shown in Figure 4B. When all of the data
points were included, the Hill regression model of the relationship
between anti-AMA1 3D7 antibodies and the homologous growth
inhibition had a good fit. The Hill coefficient was 1.70 (95% CI
1.53–1.89). The antibody level at 50% growth inhibition (Ab50)
Figure 3. Longevity of antibody responses: AMA1 antibody responses in recipients of the 20 or 80 mg AMA1-C1/Alhydrogel6CPG
7909 vaccines. Antibody responses against AMA1-3D7 (A) and AMA1-FVO (B) measured by ELISA in sera collected on Day 0 through to Day 236.
ELISA results are shown as the geometric mean of AMA1-specific antibody (mg/mL). The lines represents 80 mg AMA1 (black circles/dashed line),
20 mg AMA1+CPG (black squares/solid line), and 80 mg AMA1+CPG (black triangles/dotted line). Arrows indicate the days of vaccination.
doi:10.1371/journal.pone.0002940.g003
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PLoS ONE | www.plosone.org 9 August 2008 | Volume 3 | Issue 8 | e2940Figure 4. Functional Immunological response: Homologous in vitro parasite growth inhibition in recipients of the 20 or 80 mg
AMA1-C1/Alhydrogel6CPG 7909 vaccines. Day 70 in vitro parasite growth inhibition response against 3D7 parasites measured by GIA using
total IgG purified from individual sera. (A) Arithmetic mean of % inhibition against 3D7 parasites is shown with standard error bars. (B) The
concentration of Day 70 AMA1-specific antibody (mg/mL) to test wells (x-axis) is plotted against % inhibition (y-axis). The individual data points
represent 80 mg AMA1 (black circles, n=23), 20 mg AMA1+CPG (white squares, n=10), and 80 mg AMA1+CPG (white circles, n=25).
doi:10.1371/journal.pone.0002940.g004
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separate Hill function for each vaccine group did not create a
significantly better fit (p=0.476), so the data do not show any
significant difference in biological activity Similar results were
obtained for the FVO parasites (data not shown).
To determine whether antibodies elicited by immunization had
biologic activity against heterologous P. falciparum parasites, we
tested the activity of Day 70 purified total IgG. Due to the
limitation in volumes of purified IgGs, ten total IgG samples with
high growth-inhibitory activity to homologous parasites ($68%
inhibition to 3D7 parasites) were tested with P. falciparum L32 and
M24 parasite strains and compared to the inhibition on the
homologous 3D7 and FVO strains (Figure 5). The average
inhibition on 3D7, FVO, L32, and M24 parasites was 83%, 66%,
34%, and 28%, respectively. There were significant differences in
inhibition between all pairs of parasite strains with the ordering
3D7.FVO.L32.M24 (i.e., L32.M24, FVO.M24,
3D7.M24, etc. family-wise p=0.043).
Discussion
Local adverse reactions were more frequent and local and
systemic adverse events were significantly more likely to be more
severe when CPG 7909 was added to the AMA1-C1/Alhydrogel
vaccine. This has been seen in some previous studies using a
combination of CPG 7909 with licensed vaccines [22–24] and was
not unexpected. As with any vaccine, risk must be weighed against
benefit. For a vaccine intended to prevent severe malaria, the risk
of greater reactogenicity may be outweighed by enhanced
immunogenicity. Most adverse reactions were mild or moderate,
severe reactions were of short duration, and no serious adverse
events judged possibly, probably, or definitely related to
vaccination occurred. This safety profile was judged to be
acceptable given the greatly enhanced immunogenicity of the
AMA1-C1/Alhydrogel+CPG 7909 vaccine, and further develop-
ment of this blood-stage vaccine in malaria endemic areas.
There is a theoretical risk of inducing autoimmune disease with
CpG ODN, and markers for this were monitored frequently in this
study. One volunteer who received CPG was withdrawn from
further vaccinations after developing a transiently low positive
anti-dsDNA which subsequently returned to normal. Other studies
of CPG 7909 have also rarely seen transiently elevated anti-
dsDNA after vaccination [22]; no clinical events related to this
have been reported in studies using CPG 7909 in a vaccine to
date. ANA and RF are relatively non-specific tests of limited
usefulness in low risk populations [34,35]. In this study this is
illustrated by the high number of positive results before
vaccination, and frequent fluctuations from baseline in both the
CPG and non-CPG groups (Table 2). Three volunteers with
baseline or early elevations of ANA received three doses of vaccine
containing CPG without an increase in ANA titer; the volunteer
who had a higher titer ANA (1:1280) did not receive CPG. Less
frequent monitoring using the more specific of these markers, i.e.,
monitoring anti-dsDNA alone, and checking ANA and RF if anti-
dsDNA is positive or if clinical symptoms are present, is likely to be
sufficient for future studies.
While assessment of the safety of the vaccine formulation was
the primary goal of this study, an important secondary objective
was to determine the ability of the AMA1-C1/Alhydrogel+CPG
7909 vaccine to elicit humoral immune responses in malaria-naı ¨ve
individuals after primary vaccination and the ability to boost
memory responses with revaccination. While there was virtually
no detectable antibody response to either AMA1-FVO or AMA1-
3D7 after the first dose of 80 mg AMA1 on Day 28 in malaria-
naı ¨ve volunteers, an antibody response was detected in volunteers
who received either 20 or 80 mg of AMA1+CPG. This dramatic
increase in anti-AMA1 antibody concentrations continued to be
significant post second and third immunizations on Days 42 and
70 and to the end of the study on Day 236. The difference in
antibody concentration after the second and third immunizations
for the 80 mg AMA1+CPG group was small (1.12 fold) and non-
significant, indicating that two immunizations were sufficient to
elicit a near-maximal antibody response at this dose level. Two
weeks after the three immunizations there was also no significant
difference in AMA1 antibody concentration between 20 mg and
80 mg of AMA1-C1+CPG. Thus the addition of CPG may be
‘‘dose sparing’’, as has been observed with other CPG vaccine
clinical studies [22,23].
While there is considerable experimental support for the choice
of AMA1 as a vaccine candidate, the selection of this antigen is
potentially complicated by the fact that it displays significant
amino acid variability in different field isolates. At least 64 amino
acid residues have been shown to have one or more substitutions,
but the impact of this polymorphism with respect to protective
responses is unknown [10]. To address this issue, the AMA1-C1
vaccine was designed to include AMA1 proteins based on the
sequences of two relatively diverse P. falciparum strains: FVO and
3D7. The AMA1 sequences from these two parasite strains differ
Figure 5. Functional Immunological response: Heterologous in vitro parasite growth inhibition. Ten available samples on Day 70 with
high growth-inhibitory activity to homologous parasites ($68% inhibition to 3D7 parasites) were selected. Volunteers 10, 11 and 46 received 20 mg
AMA1+CPG; Volunteers 61, 62, 63, 88, 96 and 97 received 80 mg AMA1+CPG 7909 and Volunteer 66 received 80 mg AMA1. Day 70 in vitro parasite
growth inhibition response against 3D7 parasites (white bar), FVO (grey bar) and L32 (black bar) and M24 (hashed bar) measured by GIA using total
IgG (10 mg/mL in GIA well) purified from individual sera.
doi:10.1371/journal.pone.0002940.g005
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alleles into the AMA1-C1 vaccine, the goal was to induce a
broader immune response than could be achieved by vaccination
with either individual component alone. The anti-AMA1
antibodies induced by the AMA1-C1 vaccine recognize the native
parasite protein and inhibit growth of the FVO and 3D7 strains of
P. falciparum in vitro. The addition of CPG 7909 to the AMA1-C1/
Alhydrogel vaccine in humans elicited AMA1 specific immune
IgG that dramatically increased the growth inhibition to levels as
high as 96%. This growth-inhibitory activity was significantly
better than that from AMA1-C1/Alhydrogel in this paper as well
as what has been previously reported [16]. However, all GIA data
points could be plotted on the same curve regardless of
formulation, suggesting that the intrinsic functional activity of
the antibodies was not different with and without the addition of
CPG 7909.
Having converted the ELISA units to mg/mL and using a
widely accepted standardized GIA, it is now possible to develop a
standardized inhibitory constant such as the concentration of
AMA1 antibody required to give 50% inhibition of homologous
parasite growth (i.e. Ab50). The Ab50 could be used to compare
GIA results between blood-stage vaccine trials. However, it should
be noted that the correlation of growth-inhibitory activity with in
vivo reduction in parasite growth or protection in field trials
against clinical malaria remains to be established.
The growth inhibition of these same total IgGs on the
heterologous parasite strains L32 and M24 was not as high and
gave rise to levels approximately half or less of those observed for
the homologous FVO and 3D7 parasite strains. While heterolo-
gous inhibition was significantly decreased compared to homol-
ogous inhibition, some cross-strain inhibition was demonstrated.
To potentially further broaden protection, MVDB is developing a
second generation vaccine which will combine a third, more
divergent AMA1 allele with AMA1-C1 and which will be
evaluated in humans in the near future. Other approaches include
developing an AMA1 vaccine that incorporates a combination of
synthetic Diversity-Covering PfAMA1 sequences to provide a
broader functional immune response[15].
In conclusion, in this Phase 1 trial the AMA1-C1/Alhydro-
gel+CPG 7909 vaccine demonstrated an adequate safety profile
and was highly immunogenic in malaria-naı ¨ve individuals.
Additionally, the functional properties of these antibodies were
demonstrated by their ability to inhibit parasite growth in vitro.
AMA1-C1/Alhydrogel+CPG 7909 is currently under evaluation
in a Phase 1 endemic adult trial and if found to be safe a Phase 1
pediatric trial is planned. This would be the first use of CPG 7909
in a pediatric population for any indication.
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